{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:12:59Z","timestamp":1783825979479,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00393-024-01544-5","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:01:54Z","timestamp":1721638914000},"page":"431-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Die 2023\u00a0EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematodes\u00a0\u2013 Implikationen f\u00fcr die Versorgung in Deutschland","EULAR recommendations 2023 on the treatment of systemic lupus erythematosus\u00a0\u2014Implications for treatment in Germany"],"prefix":"10.1007","volume":"83","author":[{"given":"Johanna","family":"Mucke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J et\u00a0al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias\u00a0G, Ioannidis\u00a0JP, Boletis\u00a0J et\u00a0al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a\u00a0task force of the EULAR standing committee for International Clinical Studies including Therapeutics. AnnRheumDis 67:195\u2013205","journal-title":"Ann Rheum Dis "},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Alunno\u00a0A et\u00a0al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745","journal-title":"Ann Rheum Dis"},{"key":"1544_CR4","doi-asserted-by":"crossref","unstructured":"Van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8: e000538","DOI":"10.1136\/lupus-2021-000538corr1"},{"key":"1544_CR5","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn\u00a0K, Lau\u00a0CS, Navarra\u00a0SV et\u00a0al (2016) Definition and initial validation of a\u00a0Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615\u20131621","journal-title":"Ann Rheum Dis"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven\u00a0RF, Mosca\u00a0M, Bertsias\u00a0G et\u00a0al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958\u2013967","journal-title":"Ann. Rheum. Dis."},{"key":"1544_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00108-021-00948-8","volume":"62","author":"M Aringer","year":"2021","unstructured":"Aringer\u00a0M, Schneider\u00a0M (2021) Systemic lupus erythematosus. Internist 62:385\u2013396","journal-title":"Internist"},{"key":"1544_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor\u00a0MF, Kellner\u00a0U, Lai\u00a0TY et\u00a0al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386\u20131394","journal-title":"Ophthalmology"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/art.42645","volume":"75","author":"Y Nguyen","year":"2023","unstructured":"Nguyen\u00a0Y, Blanchet\u00a0B, Urowitz\u00a0MB et\u00a0al (2023) Association between severe Nonadherence to Hydroxychloroquine and systemic Lupus Erythematosus Flares, damage, and mortality in 660 patients from the SLICC Inception Cohort. Arthritis Rheumatol 75:2195\u20132206","journal-title":"Arthritis Rheumatol"},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/acr.25228","volume":"76","author":"S Garg","year":"2024","unstructured":"Garg\u00a0S, Chewning\u00a0B, Hutson\u00a0P et\u00a0al (2024) Reference range of Hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares. Arthritis & Rheumatism 76:241\u2013250","journal-title":"Arthritis & Rheumatism"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","volume":"81","author":"CC Almeida-Brasil","year":"2022","unstructured":"Almeida-Brasil\u00a0CC, Hanly\u00a0JG, Urowitz\u00a0M et\u00a0al (2022) Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 81:370\u2013378","journal-title":"Ann Rheum Dis"},{"key":"1544_CR12","doi-asserted-by":"crossref","unstructured":"Fasano S, Messiniti V, Iudici M et al (2023) Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med 10: e000681","DOI":"10.1136\/lupus-2022-000841"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","volume":"2","author":"D Apostolopoulos","year":"2020","unstructured":"Apostolopoulos\u00a0D, Kandane-Rathnayake\u00a0R, Louthrenoo\u00a0W et\u00a0al (2020) Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a\u00a0multicentre cohort study. Lancet Rheumatol 2:e24\u2013e30","journal-title":"Lancet Rheumatol"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros\u00a0J, Saez-Comet\u00a0L, Perez-Conesa\u00a0M et\u00a0al (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a\u00a0randomised clinical trial. Ann Rheum Dis 76:1575\u20131582","journal-title":"Ann Rheum Dis"},{"key":"1544_CR15","first-page":"S156","volume":"28","author":"M Winzer","year":"2010","unstructured":"Winzer\u00a0M, Aringer\u00a0M (2010) Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren\u2019s syndrome. ClinExpRheumatol 28:S156\u2013S159","journal-title":"Clin.Exp.Rheumatol"},{"key":"1544_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra\u00a0SV, Guzman\u00a0RM, Gallacher\u00a0AE et\u00a0al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 377:721\u2013731","journal-title":"Lancet"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie\u00a0R, Petri\u00a0M, Zamani\u00a0O et\u00a0al (2011) A phase\u00a0III, randomized, placebo-controlled study of belimumab, a\u00a0monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl\u00a0W, Schwarting\u00a0A, Okada\u00a0M et\u00a0al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a\u00a0fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69:1016\u20131027","journal-title":"Arthritis Rheumatol"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie\u00a0RA, Morand\u00a0EF, Bruce\u00a0IN et\u00a0al (2019) Type\u00a0I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a\u00a0randomised, controlled, phase\u00a03\u00a0trial. Lancet Rheumatol 1:11","journal-title":"Lancet Rheumatol"},{"key":"1544_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau\u00a0FA, Vasconcelos\u00a0C, D\u2019cruz\u00a0D et\u00a0al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61\u201364","journal-title":"Ann Rheum Dis"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau\u00a0FA, D\u2019cruz\u00a0D, Sangle\u00a0S et\u00a0al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083\u20132089","journal-title":"Ann Rheum Dis"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel\u00a0GB, Contreras\u00a0G, Dooley\u00a0MA et\u00a0al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J\u00a0Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"1544_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley\u00a0MA, Jayne\u00a0D, Ginzler\u00a0EM et\u00a0al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. Nenglj Med 365:1886\u20131895","journal-title":"Nenglj Med"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et\u00a0al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383:1117\u20131128","journal-title":"N Engl J Med"},{"key":"1544_CR26","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM et\u00a0al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase\u00a03\u00a0trial. Lancet 397:2070\u20132080","journal-title":"Lancet"},{"key":"1544_CR27","doi-asserted-by":"publisher","first-page":"e224492","DOI":"10.1001\/jamanetworkopen.2022.4492","volume":"5","author":"Z Zheng","year":"2022","unstructured":"Zheng\u00a0Z, Zhang\u00a0H, Peng\u00a0X et\u00a0al (2022) Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a\u00a0randomized clinical trial. Jama Netw Open 5:e224492","journal-title":"Jama Netw Open"},{"key":"1544_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"CC Mok","year":"2020","unstructured":"Mok\u00a0CC, Ho\u00a0LY, Ying\u00a0SKY et\u00a0al (2020) Long-term outcome of a\u00a0randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 79:1070\u20131076","journal-title":"Ann Rheum Dis"},{"key":"1544_CR29","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","volume":"81","author":"N Jourde-Chiche","year":"2022","unstructured":"Jourde-Chiche\u00a0N, Costedoat-Chalumeau\u00a0N, Baumstarck\u00a0K et\u00a0al (2022) Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a\u00a0multicentre randomised controlled trial. Ann Rheum Dis 81:1420\u20131427","journal-title":"Ann Rheum Dis"},{"key":"1544_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/rheumatology\/kes293","volume":"52","author":"DY Yap","year":"2013","unstructured":"Yap\u00a0DY, Ma\u00a0MK, Mok\u00a0MM et\u00a0al (2013) Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatol 52:480\u2013486","journal-title":"Rheumatol"},{"key":"1544_CR31","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias\u00a0GK, Ioannidis\u00a0JP, Aringer\u00a0M et\u00a0al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a\u00a0task force of the EULAR standing committee for clinical affairs. AnnRheumDis 69:2074\u20132082","journal-title":"Ann.Rheum.Dis."},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani\u00a0CD, Bejjani\u00a0A, Piazza\u00a0G et\u00a0al (2023) Direct Oral Anticoagulants vs Vitamin\u00a0K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J\u00a0Am Coll Cardiol 81:16\u201330","journal-title":"J Am Coll Cardiol"},{"key":"1544_CR33","doi-asserted-by":"crossref","unstructured":"Barbhaiya M, Zuily S, Naden R et al (2023) 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 82: 1258-1270","DOI":"10.1136\/ard-2023-224609"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01544-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:06:20Z","timestamp":1723561580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01544-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"18 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Mucke: Advisory Boards und\/oder Vortr\u00e4ge f\u00fcr AbbVie, AstraZeneca, BMS, GSK, Janssen, Lilly, Novartis und Otsuka. M.\u00a0Aringer: Advisory Boards und\/oder Vortr\u00e4ge f\u00fcr AstraZeneca, GSK, Novartis, Otsuka, Pfizer und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}